Seguimento de longo prazo de um estudo randomizado | Monoterapia com inibidor de P2Y12 vs. terapia antiplaquetária dupla (dual antiplatelet therapy – DAPT) após intervenção coronariana percutânea.
4 Out, 2022 | 12:34hLong-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link para o resumo – $ para o texto completo)
Estudo original: Randomized Trials: Shorter Duration of Dual Antiplatelet Therapy May be an Option for Patients Undergoing Percutaneous Coronary Intervention
Comentário no Twitter
In #RCT follow-up, P2Y12 inhibitor monotherapy after 3 months of DAPT found to be comparable with prolonged DAPT for preventing ischemic events. P2Y12 inhibitor monotherapy resulted in significantly lower rate of major bleeding for up to 3 yrs. https://t.co/pBv9X87lEg #Research pic.twitter.com/42Y28hPPT2
— JAMA Cardiology (@JAMACardio) September 30, 2022